Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse
Adena M, Houltram J, Mulligan SP, Todd C, Malanos G
 
 
Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.
Bibliographic details
Adena M, Houltram J, Mulligan SP, Todd C, Malanos G. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. PharmacoEconomics 2014; 32(2): 193-207
PubMedID
24442832
DOI
10.1007/s40273-013-0125-7
Indexing Status
Subject indexing assigned by NLM
MeSH
Algorithms; Antibodies, Monoclonal, Murine-Derived /administration & Antineoplastic Agents /administration & Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell /drug therapy /economics /mortality; Male; Markov Chains; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Rituximab; dosage /economics /therapeutic use; dosage /economics /therapeutic use
AccessionNumber
22014006043
Date bibliographic record published
06/03/2014
 
NHS Economic Evaluation Database (NHS EED)
Produced by the Centre for Reviews and Dissemination
Copyright © 2026 University of York
 
Homepage
Options
Print
PDF
 
PubMed record
Original research
 
Share
 

Message for NHS EED database users